Equities researchers at StockNews.com initiated coverage on shares of Enzo Biochem (NYSE:ENZ – Get Free Report) in a note issued to investors on Sunday. The brokerage set a “hold” rating on the medical research company’s stock.
Enzo Biochem Price Performance
ENZ opened at $1.12 on Friday. The stock’s 50-day moving average price is $1.12 and its 200 day moving average price is $1.13. Enzo Biochem has a 12-month low of $0.99 and a 12-month high of $1.50.
Hedge Funds Weigh In On Enzo Biochem
An institutional investor recently raised its position in Enzo Biochem stock. XTX Topco Ltd raised its stake in Enzo Biochem, Inc. (NYSE:ENZ – Free Report) by 94.5% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 28,262 shares of the medical research company’s stock after purchasing an additional 13,735 shares during the period. XTX Topco Ltd owned about 0.05% of Enzo Biochem worth $31,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 36.90% of the company’s stock.
Enzo Biochem Company Profile
Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.
Featured Stories
- Five stocks we like better than Enzo Biochem
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Ciena Stock Powers the AI Cloud Boom—Don’t Miss Out
- Stock Average Calculator
- Affirm’s Path to Profitability Elevates with Interest Rate Cuts
- 3 REITs to Buy and Hold for the Long Term
- RPM International Thrives in Rate-Cut Driven Construction Rally
Receive News & Ratings for Enzo Biochem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem and related companies with MarketBeat.com's FREE daily email newsletter.